Unmasking PD-1 Resistance by Next-Generation Sequencing.
作者： Carlo B. Bifulco , Walter J. Urba
DOI: 10.1056/NEJME1606042
关键词:
摘要: Monoclonal antibodies that inhibit the programmed death 1 (PD-1)–programmed ligand (PD-L1) pathway are clinically active against a broad range of tumors; however, even most susceptible tumors (e.g., melanoma) respond less than half time because innate resistance. In this issue Journal, Zaretsky et al.1 describe use whole-exome sequencing to identify mechanisms acquired immune resistance in from patients with melanoma who had relapse after more 6 months tumor response treatment pembrolizumab. Tumor regression PD-1–PD-L1 blockade is presumed be mediated by activation tumor-infiltrating . . .
sci-hub.se 参考文章(10)
Stefani Spranger, Riyue Bao, Thomas F. Gajewski, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity Nature. ,vol. 523, pp. 231- 235 ,(2015) , 10.1038/NATURE14404
Michael T Spiotto, Donald A Rowley, Hans Schreiber, Bystander elimination of antigen loss variants in established tumors. Nature Medicine. ,vol. 10, pp. 294- 298 ,(2004) , 10.1038/NM999
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio J. Gutierrez, Tristan R. Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan O. Emerson, Harlan Robins, Robert H. Pierce, David A. Elashoff, Caroline Robert, Antoni Ribas, PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature. ,vol. 515, pp. 568- 571 ,(2014) , 10.1038/NATURE13954
C M D'Urso, Z G Wang, Y Cao, R Tatake, R A Zeff, S Ferrone, Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. Journal of Clinical Investigation. ,vol. 87, pp. 284- 292 ,(1991) , 10.1172/JCI114984
Weiyi Peng, Jie Qing Chen, Chengwen Liu, Shruti Malu, Caitlin Creasy, Michael T. Tetzlaff, Chunyu Xu, Jodi A. McKenzie, Chunlei Zhang, Xiaoxuan Liang, Leila J. Williams, Wanleng Deng, Guo Chen, Rina Mbofung, Alexander J. Lazar, Carlos A. Torres-Cabala, Zachary A. Cooper, Pei-Ling Chen, Trang N. Tieu, Stefani Spranger, Xiaoxing Yu, Chantale Bernatchez, Marie-Andree Forget, Cara Haymaker, Rodabe Amaria, Jennifer L. McQuade, Isabella C. Glitza, Tina Cascone, Haiyan S. Li, Lawrence N. Kwong, Timothy P. Heffernan, Jianhua Hu, Roland L. Bassett, Marcus W. Bosenberg, Scott E. Woodman, Willem W. Overwijk, Gregory Lizée, Jason Roszik, Thomas F. Gajewski, Jennifer A. Wargo, Jeffrey E. Gershenwald, Laszlo Radvanyi, Michael A. Davies, Patrick Hwu, Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Cancer Discovery. ,vol. 6, pp. 202- 216 ,(2016) , 10.1158/2159-8290.CD-15-0283
Willy Hugo, Jesse M. Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Shirley Lomeli, Xiangju Kong, Mark C. Kelley, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Roger S. Lo, Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma Cell. ,vol. 165, pp. 35- 44 ,(2016) , 10.1016/J.CELL.2016.02.065
Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana M. Kulkarni, Mari Kuraguchi, Sangeetha Palakurthi, Peter E. Fecci, Bruce E. Johnson, Pasi A. Janne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok-Kin Wong, Peter S. Hammerman, Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications. ,vol. 7, pp. 10501- 10501 ,(2016) , 10.1038/NCOMMS10501
Weijie Ma, Barbara M. Gilligan, Jianda Yuan, Tianhong Li, Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Journal of Hematology & Oncology. ,vol. 9, pp. 47- 47 ,(2016) , 10.1186/S13045-016-0277-Y
Jesse M. Zaretsky, Angel Garcia-Diaz, Daniel S. Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Davis Y. Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly, Justin Saco, Blanca Homet Moreno, Riccardo Mezzadra, Bartosz Chmielowski, Kathleen Ruchalski, I. Peter Shintaku, Phillip J. Sanchez, Cristina Puig-Saus, Grace Cherry, Elizabeth Seja, Xiangju Kong, Jia Pang, Beata Berent-Maoz, Begoña Comin-Anduix, Thomas G. Graeber, Paul C. Tumeh, Ton N.M. Schumacher, Roger S. Lo, Antoni Ribas, Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma The New England Journal of Medicine. ,vol. 375, pp. 819- 829 ,(2016) , 10.1056/NEJMOA1604958
Leticia Corrales, Sarah M. McWhirter, Thomas W. Dubensky, Thomas F. Gajewski, The host STING pathway at the interface of cancer and immunity Journal of Clinical Investigation. ,vol. 126, pp. 2404- 2411 ,(2016) , 10.1172/JCI86892